Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Taysha Gene Therapies (TSHA) EBITDA (2022 - 2025)

Historic EBITDA for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to -$34.0 million.

  • Taysha Gene Therapies' EBITDA fell 3137.69% to -$34.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$102.1 million, marking a year-over-year decrease of 1635.7%. This contributed to the annual value of -$91.5 million for FY2024, which is 2625.66% down from last year.
  • As of Q3 2025, Taysha Gene Therapies' EBITDA stood at -$34.0 million, which was down 3137.69% from -$26.8 million recorded in Q2 2025.
  • In the past 5 years, Taysha Gene Therapies' EBITDA registered a high of -$16.2 million during Q4 2023, and its lowest value of -$54.0 million during Q4 2022.
  • Over the past 4 years, Taysha Gene Therapies' median EBITDA value was -$24.3 million (recorded in 2024), while the average stood at -$27.2 million.
  • As far as peak fluctuations go, Taysha Gene Therapies' EBITDA skyrocketed by 6989.59% in 2023, and later crashed by 5937.23% in 2024.
  • Quarter analysis of 4 years shows Taysha Gene Therapies' EBITDA stood at -$54.0 million in 2022, then skyrocketed by 69.9% to -$16.2 million in 2023, then decreased by 22.69% to -$19.9 million in 2024, then tumbled by 70.7% to -$34.0 million in 2025.
  • Its EBITDA stands at -$34.0 million for Q3 2025, versus -$26.8 million for Q2 2025 and -$21.4 million for Q1 2025.